NCT00255684 · STUDY IN CONTEXT

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Tr

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Number of Participants Who Survived 100 Days or Longer

Source null

→

secondary · POSTED

Number of Participants Who Developed Acute Graft Versus Host Disease

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-myeloproliferative-neoplasms
nct id: NCT00255684
trial label: Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Tr
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 2
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-myeloproliferative-neoplasms
nct id
NCT00255684
outcome key
om-0000
source section id
NCT00255684-om-0000
source outcome index
0
endpoint
Number of Participants Who Survived 100 Days or Longer
endpoint definition
Number of Participants Who Survived 100 Days or Longer
time origin
100 days
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-myeloproliferative-neoplasms
nct id
NCT00255684
outcome key
om-0001
source section id
NCT00255684-om-0001
source outcome index
1
endpoint
Number of Participants Who Developed Acute Graft Versus Host Disease
endpoint definition
Number of Participants Who Developed Acute Graft Versus Host Disease
time origin
3 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-myeloproliferative-neoplasms
nct id
NCT00255684
outcome key
om-0000
arm key
OG000
arm label
Conditioning Therapy Followed by TBI
regimen
Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil graft-versus-tumor prophylaxis therapy cyclophosphamide cyclosporine fludarabine phosphate mycophenolate mofetil umbilical cord blood transplantation radiation therapy
analyzed count
16
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00255684-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-myeloproliferative-neoplasms
nct id
NCT00255684
outcome key
om-0001
arm key
OG000
arm label
Conditioning Therapy Followed by TBI
regimen
Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil graft-versus-tumor prophylaxis therapy cyclophosphamide cyclosporine fludarabine phosphate mycophenolate mofetil umbilical cord blood transplantation radiation therapy
analyzed count
16
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00255684-om-0001#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-myeloproliferative-neoplasms
nct id
NCT00255684
harm key
EG000
source section id
NCT00255684-ae
event group key
EG000
event group label
Conditioning Therapy Followed by TBI
serious affected
11
serious at risk
16
other affected
0
other at risk
16
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice